Oncology

Oncology Drug Discovery & Development

Millions of people around the world are affected by cancer each year, with hundreds of distinct cancer types distinguished by specific underlying mutations, affected cell types, etc. The search for novel treatments for all of these cancers is one of the foremost missions of modern scientific research. Our team is committed to advancing this goal through the provision of high-quality screening and proteomic services that facilitate all stages of the oncology drug discovery and development process.

Our Protein Turnover Atlas™ database includes protein half-life data from several common cancer-associated mutations (including KRAS G12C and G12D) to support research efforts. We have experience working with a wide variety of cancer cell lines, targets, and mutants to characterize underlying biology and accelerate pharmaceutical development. All of our proteomic, chemoproteomic, and small-molecule profiling services can be readily applied to cancer cell lines and tumor samples to optimize therapeutic activity, identify biomarkers of disease progression or treatment efficacy, or characterize cellular dysfunction. The Momentum team is proud to support oncology drug discovery and development for scientists worldwide as they develop next-generation cures for devastating cancers.